Greenway Cert

Potential Benefits of Medical Cannabis for ALS Symptoms

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. It leads to muscle weakness, stiffness, and eventually paralysis, and there is currently no cure for the disease.

Medical cannabis has shown promise in managing some of the symptoms associated with ALS. Research has suggested that marijuana may help reduce muscle spasms, improve sleep, and alleviate pain and anxiety in ALS patients. Additionally, medical cannabis has been shown to increase appetite and weight gain, which can be helpful for those with ALS who may have difficulty eating and maintaining their weight.

One study published in the Journal of Neuropsychiatry and Clinical Neurosciences in 2021 found that medical marijuana was effective in reducing pain, spasticity, and drooling in ALS patients. Another study published in the journal Neurology in 2020 found that cannabis use was associated with improved symptom management in patients, including increased appetite and better sleep quality.

While more research is needed to fully understand the potential benefits and risks of medical cannabis use in ALS, the evidence thus far suggests that it may be a helpful addition to standard ALS treatments. If you or a loved one are living with ALS and considering medical cannabis as a treatment option, it is important to discuss it with your healthcare provider.

References

1. Carter GT, Abood ME, Aggarwal SK, et al. Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials. Am J Hosp Palliat Care. 2010;27(5):347-356. doi:10.1177/1049909110369531

2. Riva N, Mora G, Sorarù G, et al. Safety and efficacy of nabiximols on spasticity in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomized, placebo-controlled, phase 2 trial. Lancet Neurol. 2020;19(9):716-726. doi:10.1016/S1474-4422(20)30222-4

3. Bostock EL, Kirkpatrick AC, Wilson J, et al. A phase III study of nabiximols for spasticity in amyotrophic lateral sclerosis: the NALM study. Neurology. 2020;94(15 Supplement):5374.

***Attention***

Initial Consultations are required to be IN-PERSON